Therapeutic Areas
16 therapeutic areas across 5,646 disease indications and 111,688 active pipeline programs. Click any area to see the drug pipeline, competitive landscape, and hiring signals for that category.
Oncology
25,699Cancer drug R&D — solid tumors, hematologic malignancies, and targeted therapies. Watch for ADCs, bispecifics, and CDK4/6 inhibitor patent cliffs.
Neurology
7,741CNS disorders including Alzheimer's, Parkinson's, MS, ALS, and migraine. High unmet need and long regulatory timelines — commercial teams form 12-18 months before approval.
Metabolic Diseases
7,116Cardiovascular
6,344Respiratory
4,640Asthma, COPD, IPF, and respiratory infection. Biologics for severe asthma and novel small molecules for IPF drive recent activity.
Immunology
4,052Autoimmune and inflammatory disease — rheumatoid arthritis, psoriasis, IBD, atopic dermatitis. JAK inhibitors, biologics, and oral small molecules compete for share.
Ophthalmology
2,237Age-related macular degeneration, diabetic retinopathy, glaucoma, and dry eye. Anti-VEGF intravitreal injections remain dominant; new gene therapies approved.
Nephrology
1,980Chronic kidney disease, ADPKD, and dialysis-related complications. SGLT2 inhibitors (Farxiga, Jardiance) and GLP-1s cross over from CV/T2D.
Rare Diseases
1,708Gastroenterology
1,354Crohn's, ulcerative colitis, IBS, hepatitis, and NASH. IBD biologics have exploded; NASH is an open frontier.
Hematology
744Blood cancers, sickle cell disease, hemophilia, and thrombotic disorders. Gene therapies (Casgevy, Lyfgenia) and novel factor replacements are recent approvals.
Dermatology
660Psoriasis, atopic dermatitis, acne, and aesthetics. Topical JAK inhibitors + IL-23 biologics continue to expand.
Endocrinology
487Diabetes, obesity, thyroid, and metabolic disease. GLP-1 agonists are the fastest-growing commercial franchise in pharma — Wegovy, Ozempic, Mounjaro, Zepbound.
Women's Health
427Contraception, menopause, endometriosis, fertility, and postpartum depression. Digital therapeutics + new hormonal options.
Vaccines
195How we organize therapeutic areas
Formulate maps each drug and clinical trial to one or more therapeutic areas based on approved indications and active study conditions. When a drug crosses areas (e.g., Ozempic — Endocrinology and Nephrology), it appears under both. Counts reflect live data from ClinicalTrials.gov, the FDA, and SEC filings.